To understand the relationships between the non-GCIMP glioblastoma (GBM) subgroups, we performed mathematical modeling to predict the temporal sequence of driver events during tumorigenesis. The most common order of evolutionary events is 1) chromosome (chr) 7 gain and chr10 loss, followed by 2) CDKN2A loss and/or TP53 mutation, and 3) alterations canonical for specific subtypes. We then developed a computational methodology to identify drivers of broad copy number changes, identifying PDGFA (chr7) and PTEN (chr10) as driving initial nondisjunction events. These predictions were validated using mouse modeling, showing that PDGFA is sufficient to induce proneural-like gliomas and that additional NF1 loss converts proneural to the mesenchymal subtype. Our findings suggest that most non-GCIMP mesenchymal GBMs arise as, and evolve from, a proneural-like precursor.
INTRODUCTION
Glioblastomas (GBMs) are the most common and malignant CNS neoplasms and arise initially as grade 4 tumors (primary GBM) or evolve from lower-grade gliomas (secondary GBM). Deep molecular analyses of primary GBMs have divided them into four classes: proneural (PN), mesenchymal (MES), classical (CL), and neural (NL) Phillips et al., 2006; Verhaak et al., 2010) . However, in some cases, the division is blurred in that a sample might show patterns of more than one subtype Phillips et al., 2006; Sottoriva et al., 2013; Verhaak et al., 2010) . These subclasses can be associated with canonical mutations such as PDGFRA amplification in PN GBM, loss of NF1 in MES GBM, and amplification of EGFR in CL GBM. In the case of NL GBMs, particular molecular abnormalities remain unidentified.
One of the best-studied GBM subclasses is PN GBM, some of which carrying mutant IDH1 or IDH2 and have the methylator phenotype denoted by glioma-CpG island methylator phenotype (GCIMP) (Noushmehr et al., 2010) . Although the transcriptomal patterns for GCIMP tumors resemble those of the other PN GBMs (non-GCIMP), their biology is significantly different in that the GCIMP GBMs display global hypermethylation of CpG islands, characteristic copy number Significance Deep molecular analyses have divided non-GCIMP GBMs into four classes, but the relationship between these subtypes is unknown. Here we combined computational and mathematical analyses of human GBM data with mouse modeling and found that these tumors appear to be initiated by broad genomic alterations driven partly by increased PDGFA expression and PTEN loss and evolve from a common glioma precursor that is lethal and proneural in character. The acquisition of secondary molecular subtype characteristics by EGFR and PDGFRA amplification or NF1 loss is achieved late in GBM evolution. Our findings provide insights into the natural history of GBMs and therapeutic strategies targeting these late events.
alterations, and prolonged patient survival, suggesting that these tumors represent high-grade versions of grade 2 and 3 diffuse gliomas, which are commonly GCIMP and, thus, represent secondary GBMs (Noushmehr et al., 2010; Ohgaki and Kleihues, 2013) .
The existence of different GBM subtypes raises questions regarding their natural history and the temporal sequence in which individual alterations arise (Bhat et al., 2013; Phillips et al., 2006; Sottoriva et al., 2013) . Furthermore, it is unclear whether these subgroups are fundamentally different tumors from their inception or whether they evolve from a common glioma precursor. Given the evidence of spontaneous conversion of human PN to MES tumors and observed subtype mosaicism within the same tumor (Phillips et al., 2006; Sottoriva et al., 2013) , the GBM subtypes might be directionally variable from one subtype to another. Finally, it remains unclear whether the existence of subgroups has therapeutic implications (Bhat et al., 2013) . For example, the subtype-defining mutations may be promising therapeutic targets if they represent initiating genetic events in glioma evolution, but their inhibition would likely not provide a lasting therapeutic benefit if they represent late events.
Chromosome instability is common in human cancers. It is characterized by widespread chromosome (chr) copy number changes, such as gain or loss of whole chr or fractions thereof (Lengauer et al., 1998) . Gain of chr7 as well as loss of chr10 and parts of chr9 are very frequent in gliomas. Alteration of chr7 frequently includes focal amplification of the EGFR locus (The Cancer Genome Atlas Research Network, 2008) . Nevertheless, forced expression of the wild-type epidermal growth factor receptor (EGFR) or the constitutively active EGFRvIII mutant alone does not form gliomas in mice Zhu et al., 2009) , suggesting that EGFR might not be an initiator of this tumor type.
Genome-wide high throughput sequencing efforts have led to the identification of many genomic alterations in cancer genomes, but it remains a challenge to identify genuine driver genes from the many genes located within a large chromosomal event. Here we utilized a combined computational and experimental approach to investigate the natural history of human non-GCIMP GBMs.
RESULTS
We first utilized genomic data from The Cancer Genome Atlas (TCGA) to investigate the frequencies and types of genomic alterations in GBM (The Cancer Genome Atlas Research Network, 2008) . The overall pattern of broad gains and losses in the GCIMP tumors showed some similarities to that in the non-GCIMP PN GBM (Noushmehr et al., 2010) but were strikingly similar between the non-GCIMP PN GBM and other non-GCIMP subtypes ( Figure 1A ; Table S1 available online). These patterns suggest that all non-GCIMP GBMs are very similar with respect to genomic alterations acquired during their evolution and distinct from the GCIMP tumors. We then performed a phylogenetic analysis of copy number, mRNA expression, somatic mutations, and promoter methylation data of the non-GCIMP subgroups and found that PN GBMs located separately on the phylogenetic trees generated by each of these data types, suggesting that they are distinct from other non-GCIMP subtypes ( Figure 1B) .
Gain of several copies of chr7 and loss of one copy of chr10 were the most frequent events in non-GCIMP GBMs, with frequencies of 86% and 90%, respectively (Figures 1A and 1C) . GCIMP tumors almost never lose the entire chr10 but show similar frequencies of loss (26%) and amplification (24%) of 10p ( Figures 1A and 1C) . Note that gain of chr7 refers to the gain of a few copies of the whole chr7, which is different from amplification of any specific gene on chr7, and loss of chr10 refers to the loss of a whole copy of chr10 but leaving the other copy intact, which is not synonymous with focal deletion of any gene on chr10. These events are distinct from the commonly reported high-level amplification and deletion of specific genes in GBMs, such as PDGFRA, EGFR, or MET (The Cancer Genome Atlas Research Network, 2008) .
When investigating 7p and 7q separately for all GBM subtypes, we found that 7p gain ranged from 81% for PN GBMs to 95% for MES GBMs, whereas 7q gain ranged from 79% for PN GBMs to 93% for MES GBMs ( Figure 1C ). In general, 7p and 7q gain were balanced ( Figure 1D ), with the exception of GCIMP tumors, in which 7q gain occurred in 24% of tumors and 7p gain in 15%. These data imply that, for non-GCIMP GBMs, chr7 is gained as the entire chromosome. Balanced chr7 gain is present in 82% of all non-GCIMP GBM samples and represents the most common chromosomal abnormality in these tumors. Non-GCIMP cases with a normal copy number of both chr7 and chr10 were rare (2%) ( Figure S1A ; Tables S2  and S3 ) and had a similar age and survival distribution as GCIMP tumors (Figures S1B and S1C), suggesting that some of these non-GCIMP cases are potentially misclassified GCIMP tumors ( Figure S1D ).
Mathematical Modeling Suggests Gain of Chr7 and Loss of Chr10 as First Events in All Non-GCIMP GBM Subtypes
The high prevalence and even distribution of chr7 gain and chr10 loss in all non-GCIMP GBM subtypes raises the question of when these events occur during GBM development. Therefore, we utilized a computational methodology, Retracing Evolutionary Steps in Cancer (RESIC), to determine the temporal sequence of genetic alterations during tumorigenesis from cross-sectional genomic data of a population of tumors at their fully transformed stage (see also Supplemental Experimental Procedures) Cheng et al., 2012) . Applying RESIC to TCGA data (The Cancer Genome Atlas Research Network, 2008) to examine the temporal order of the known subtype-specific alterations EGFR (CL GBM), NF1 (MES GBM), and PDGFRA (PN GBM) (Verhaak et al., 2010) , together with gain of chr7 and loss of chr10, we identified chr7 gain together with chr10 loss as the first event in all subtypes of GBM (Figure 2A ; Figures S2A and S2B ). Loss of CDKN2A was another early event in all subtypes. Further analyses based on samples with mutational information only (n = 85 for non-GCIMP samples) revealed that TP53 mutations arose after CDKN2A loss ( Figure 2B ; Figure S2C ). Finally, when considering all frequent chromosome arm-level events, we found that chr7 gain and chr10 loss arise before any other broad gains or losses ( Figure 2C ; Figure S2D ). An almost identical ordering of these events was inferred using a different method (Beerenwinkel and Sullivant, 2009) (Figure S2E ).
To delineate the clinical implications of these arm-level events, we investigated the association between chr7 gain or chr10 loss and GBM patient survival. Copy numbers of chr7 and chr10 correlate negatively and positively, respectively, with survival ( Figures 3A and 3B ). This finding arises primarily because these events do not occur as frequently in GCIMP tumors and because patients with these tumors survive longer, on average, than patients with non-GCIMP GBMs (Noushmehr et al., 2010) . However, even in the non-GCIMP GBMs, chr7 gain correlates with poor survival of patients, but only in the case of PN GBM (Figure 3A) . These data suggest that a gene or several genes on chr7 drive the gain of copy number early in GBM evolution and promote the aggressive character in PN GBM. By contrast, the lack of association of chr10 loss with overall survival might be due to haplosufficiency of genes on chr10 ( Figure 3B ).
Computational Analysis Suggests PDGFA and PTEN as Major Drivers of Nondisjunction Events We aimed to identify the genes on chr7 and chr10 that drive the acquisition of these arm-level events, lead to the poor survival of patients, and are potential targets for therapies. We designed a computational algorithm consisting of two steps. The first step ranks genes based on the extent of correlation between their copy number and expression levels. Genes are first sorted by the fold change of expression between tumors that do and do not harbor the arm-level event. Genes with anticorrelation of copy number and mRNA levels are excluded. In the second step, the resulting gene list is filtered further by the degree of correlation between a gene's expression level and patient survival.
When applying the first step to genes on chr7 for all non-GCIMP GBM samples, we identified a set of genes with the highest expression response to increased copy number predicted to (proneural, neural, mesenchymal, and classical GBM) . (B) Phylogenetic analysis in all GBM samples determining the putative evolutional order in GBM subtypes using all data types (copy number, mRNA expression, somatic mutation, and methylation) and the Neighbor Joining algorithm. Artificial samples with exactly two copies in the whole genome serve as a normal copy number control. For the DNA methylation analysis, the HM27 and HM450 platforms are shown. (C) Histograms showing the frequencies of whole arm gains and losses of both chr7 and chr10 in each subtype separately. Homozyg., homozygous; Amp., amplification. (D) Copy numbers of the p and q arms of chr7 and chr10 for all TCGA samples stratified by GBM subtype. See also Figure S1 and Tables S1, S2, and S3. occur with gain of chr7 ( Table S4 ). Note that EGFR was not selected in this first filtering because a low-level gain of EGFR, as found with whole chr7 gain, is not correlated with its increased expression (p = 0.19, Student's t test, EGFR normal versus gain, Figure S3A ). High-level amplification of EGFR is predicted by RESIC to be a late event (Figure 2A ), and such focal amplification of EGFR correlates significantly with its expression level (p < 0.001, Student's t test, EGFR gain versus focal amplification, Figure S3A ). Almost all identified point mutations in EGFR as well as in EGFRvIII were found in samples with high-level focal gene amplification ( Figure S3A ; Table S1 ). These data further support the hypothesis that EGFR may not be a driver of initial oncogenic events in this tumor type but, rather, contributes to tumor progression or maintenance through high expression driven by focal amplification arising at later stages of tumor formation.
The second step then showed that a direct correlation between expression levels and survival was uninformative because many genes on chr7 displayed a correlation between their copy number and expression. Thus, their expression also correlates with survival in PN GBM (Table S4) . Therefore, we investigated the correlation between survival and the expression levels of pathways downstream of genes on chr7. When applying this filter to chr7, we found that, of the 190 genes whose expression fold change between cases of normal and gained chr7 copy number was at least 1.25, 13 genes displayed a correlation with survival in PN GBMs of p < 0.05 (Table S5 ). Figure 3C summarizes the two filters applied to chr7. This combined ranking approach identified PDGFA as the highest-ranking gene on chr7 ( Figure S3B ; Tables S5 and S6), i.e., expression of PDGFA downstream genes was associated with overall survival, and chr7 gain increased PDGFA mRNA levels significantly. Therefore, PDGFA most likely is the gene providing the strongest selective advantage to gaining extra copies of chr7.
We then sought to identify potential drivers of chr10 loss. The application of the two steps outlined above is only appropriate for chromosomal gains because the correlation between expression levels and patient outcomes necessitates a degree of variability in copy number across patients. Chr7 gain meets this requirement because patients may harbor three, four, or more copies of chr7. By contrast, chr10 loss results in a single remaining copy of chr10 in almost all cases ( Figures 1C and 1D ), therefore necessitating an alternative strategy. Because loss of chr10 and gain of chr7 almost always co-occur (p = 0.001, Fisher's exact test, Figures 1A and 1C ), we hypothesized that the phenotypic effect of a main driver of chr10 loss might amplify the effects of the driver of chr7 gain and vice versa, therefore likely activating the same pathways and resultant changes in gene expression. We also ranked the genes on chr10 by the association of the expression levels of their downstream genes with survival (Tables S4 and S5 ). The tumor suppressor PTEN displayed a highly significant survival association between the expression levels of its downstream genes and survival (false discovery rate [FDR] < 0.02) ( Figure 3D ; Figure S3C;  Table S5 ) and also a large overlap of downstream genes of PDGFA ( Figure 3E ), suggesting that it may be a significant driver of chr10 loss in these tumors. In non-GCIMP GBM subtypes other than PN GBMs, we did not identify any such strong pathway enrichments of chr7 and chr10, consistent with the lack of correlation of chr7 gain with survival in these GBM subtypes ( Figure 3A ). Our computational approach therefore suggests PDGFA and PTEN as primary drivers of the chr7 and chr10 nondisjunction events, respectively. Note that this analysis does not suggest that these genes alone are sufficient for driving these events.
Mouse Modeling Suggests that the Predicted First Events in Glioma Evolution Are Sufficient to Induce Gliomagenesis
Our computational analyses predict that elevated expression of PDGFA represents the strongest initial driving event in glioma evolution. This is noteworthy because of the well described role of PDGF signaling in GBM, especially in PN GBM The Cancer Genome Atlas Research Network, 2008; Verhaak et al., 2010) . Note that the elevated expression of PDGFA as a likely driver is not the same as the frequently reported high-level focal amplification of PDGFRA found primarily in PN GBM. The PDGF signaling network is transmitted by four ligands (A, B, C, and D isoforms) and two protein tyrosine kinase receptors (a and b). Overexpression of PDGFB generates PDGFB homodimers (BB dimers) that activate both PDGFRa and b, whereas overexpression of PDGFA only activates PDGFRa (Andrae et al., 2008; Heldin and Westermark, 1999) . In animal modeling systems, signaling driven by PDGFB alone is sufficient to form GBMs, and additional loss of Tp53, Cdkn2a (Ink4a-Arf), or Pten accelerates tumor formation (Dai et al., 2001; Fomchenko et al., 2011; Hu et al., 2005; Shih et al., 2004; Squatrito et al., 2010 ). Although the PDGFB protein level is elevated in many PN GBMs, it does not correlate with the PDGFB mRNA level in these tumors . Moreover, the alteration of PDGFB is rare in GBMs (Verhaak et al., 2010) , suggesting that other PDGFs, such as PDGFA, could potentially drive oncogenesis in this GBM subtype. However, it remains to be determined whether elevated PDGFA is sufficient to initiate gliomas, either alone or in combination with other early events such as CDKN2A, TP53, or PTEN loss (Figures 2A and 2B ; Figures S3C and S3D) (Jackson et al., 2006; Nazarenko et al., 2011 ). Therefore, we tested the ability of genes predicted to drive human GBM evolution to induce gliomas in vivo using the replication-competent avian sarcoma-leukosis virus long terminal repeat with splice acceptor/tumor virus a (RCAS/tv-a) system that allows postnatal cell type-specific gene transfer . To determine whether PDGFA alone is sufficient for glioma formation, we infected neonatal N/tv-a mice (Nestin-expressing cell of origin, n = 11) and G/tv-a mice (GFAP-expressing cell of origin, n = 14) with an RCAS retroviral vector expressing human PDGFA (RCAS-PDGFA) (Figures S4A and S4B) . All N/tv-a mice were sacrificed at 4 months of age, when the first mice developed symptoms of intracranial pathology. Eight of eleven mice harbored brain tumors of various sizes demonstrating histological features of grade 2 human oligodendrogliomas, including round nuclei, perinuclear halos, and strong Olig2 and lower GFAP expression ( Figure S3 and Tables S4, S5 , and S6.
ure 4A and data not shown). All G/tv-a mice formed tumors ranging from 159-323 days postinjection. Many developed high-grade gliomas with histologic features of human oligodendroglioma ( Figure 4B ; Figure S4C ). These data indicate that elevated PDGFA expression is sufficient to initiate gliomagenesis in vivo.
Pten Loss Shortens Survival of Mice with PDGFAInduced Gliomas but Is Not Sufficient to Induce Gliomas Alone RESIC analysis predicted that combined loss of chr10 and gain of chr7 are the earliest events in non-GCIMP GBM subtypes. Previous results using the RCAS/tv-a system have shown that loss of Pten alone is insufficient for glioma formation in mice (Hu et al., 2005) , suggesting that loss of Pten might play a supportive role in PDGFA-responsive cells rather than serving as the tumor initiator. To confirm the supportive role of Pten loss in this context, we created an RCAS vector expressing mRFP and a short hairpin designed to knock down Pten expression (RCAS-shPten) ( Figures S4A, S4D , and S4E). Infection of both wild-type N/tv-a (n = 3) and G/tv-a (n = 11) mice with this vector alone did not result in brain tumors by approximately 4 months of age. However, consistent with the RESIC prediction, simultaneous Pten loss significantly shortened the survival of mice with PDGFA-induced gliomas and elevated the grade of the tumors (Figures 4A and 4B; Figures S4F-S4H ). These features were also observed in a cre-mediated Pten deletion model ( Figure 4B ; Figure S4F ).
PDGFA-Induced Tumors Resemble PN GBMs, but PDGFB-Induced Tumors Display a More MES GBM-like Character RESIC analysis also predicted that loss of CDKN2A occurs after gain of chr7 (elevation of PDGFA expression) in these tumors. Therefore, we injected neonatal N/tv-a;Cdkn2a(Ink4a-Arf) À/À mice with RCAS-PDGFA (n = 25) ( Figure 4C ). Tumors occurred
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Non-GCIMP GBM Evolves from a Common PN Precursor in these mice with 100% penetrance and a median survival of 65 days. These tumors demonstrated histological features of human oligodendroglioma and displayed a high-grade histology with uniformly abundant pseudopalisading necrosis, hypervascularity, and brisk microvascular formation throughout the tumor (Figures 4C and 4D ; Figure S4I ). Interestingly, additional loss of Pten in a Cdkn2a À/À background did not shorten tumor latency further ( Figure 4C ). We then compared gliomas induced by PDGFA and PDGFB in newborn and adult N/tv-a;Cdkn2a À/À mice. We found that PDGFA generated tumors with a longer latency than PDGFB and that gliomas induced by either ligand arose in newborn mice faster than in adults ( Figure 4C ; Figure S4J ) . The histology of tumors induced by PDGFA and PDGFB was generally similar. However, the vasculature and stroma were notably different ( Figure 4D ; Figure S4K ). PDGFBinduced gliomas showed a spindled vasculature and atypical stroma (PDGFB activates both a receptors in the tumor cells as well as b receptors in the perivascular stroma), whereas tumors generated by PDGFA (which activates only the a receptor) ;Pten fl/fl mice. Gene expression profiles were compared between the PDGFA-induced (n = 7) and PDGFB-induced (n = 5) gliomas based on the TCGA subtype signatures (Verhaak et al., 2010) . Bar plots visualize enrichment p values (y axis) of the four subtype signatures in the ranking of genes by differential expression (PDGFA versus PDGFB). A low p value indicates consistent expression with the subtype, i.e., many genes known to be upregulated in the subtype are up, and downregulated genes are down.
(F) GSEA of the RCAS-PDGFA/shp53-and RCAS-shNf1/shp53-induced gliomas in N/tv-a and G/tv-a mice. See also Figure S4 and Table S7. showed glomeruloid microvascular proliferation more similar to that seen in human GBM ( Figure 4D ; Figure S4K ) Hermansson et al., 1988) . Subsequently, we profiled these tumors by gene expression analysis to determine which human GBM subtype they resembled most closely and found that PDGFA-induced gliomas in the mouse more closely resembled PN GBMs in humans, whereas the PDGFB-induced tumors shifted toward MES GBMs ( Figure 4E ). The Olig2-expressing tumor cells from PDGFB-induced gliomas, which constitute the bulk of the tumor (Figure 4D ), show a strongly proneural expression profile (Dougherty et al., 2012) . Therefore, the MES character of the PDGFB-induced gliomas possibly reflects the abundant atypical perivascular stroma and other nontumor stromal cell types found in these tumors (Figures 4D and 4E ; Figure S4K ).
Loss of TP53 as well as PTEN or CDKN2A in PDGFA-Induced Gliomas Results in a Highly Lethal Disease in Mice CDKN2A loss occurs frequently in human PN GBMs, but this GBM subgroup also commonly harbors mutations in TP53 (Verhaak et al., 2010) . Therefore, we determined whether loss of Tp53 would cooperate with PDGFA-induced gliomas in a similar way as Cdkn2a loss. We generated an RCAS vector expressing both mRFP and a short hairpin designed to knock down Tp53 expression (RCAS-shp53) ( Figures S4A and S4L-S4P ). Infecting mice with this vector alone did not generate gliomas by approximately 1 year of age. However, when combined with RCAS-PDGFA, high-grade gliomas formed in 100% of mice with a median survival of 69.5 days in wild-type N/tv-a mice (n = 18) and 56 days in wild-type G/tv-a mice (n = 31), similar to PDGFA in a Cdkn2a À/À background ( Figures 4AÀ4C) . The tumors demonstrated histological features of human oligodendroglioma and displayed a high-grade histology similar to PDGFA-induced tumors with Cdkn2a loss ( Figure S4Q ). Furthermore, the gene expression profiles of the gliomas induced by PDGFA with loss of Tp53 showed a significant enrichment of PN GBM genes ( Figure 4F ) as well as downstream orthologs of human PDGFA identified in the abovementioned computational analysis ( Figure 3C ; Figure S4R ; Table S6 ). These observations suggest that loss of the tumor suppressor genes PTEN, CDKN2A, or TP53 is sufficient to enhance PDGFA-induced gliomas, resulting in highly lethal gliomas.
Simultaneous Loss of Nf1 and Tp53 Induces MES GBM in the RCAS/tv-a Model RESIC analysis predicts that the same early events in PN GBM also occur in MES GBM but that NF1 loss occurs late in the evolution of these tumors. In MES GBMs (as well as all non-GCIMP GBMs), NF1 loss is associated with TP53 mutations and, less commonly, with CDKN2A loss ( Figure S5A ) (Verhaak et al., 2010) . Furthermore, published mouse GBM models resulting from germline homozygous deletions of Nf1 and Tp53 show a median survival of approximately 150-200 days (Reilly et al., 2000; Zhu et al., 2005) , but they do not recapitulate a human MES GBM expression pattern (Liu et al., 2011 More importantly, all of these GBM models were generated using technologies different from what we used, making it difficult to compare them. Therefore, to allow direct comparison of our PDGFA models and mouse models of MES GBM, we engineered the RCAS/tv-a system to generate MES GBM from normal cells. We then set out to initially reproduce the published effect of combined loss of Nf1 and Tp53. We created an RCAS vector expressing GFP and a short hairpin designed to knock down Nf1 expression (RCAS-shNf1) ( Figures S4A, S4L, S4N , S4O, S5B, and S5C). Infection of both wild-type N/tv-a (n = 20) and G/tv-a (n = 12) mice with this vector alone did not generate tumors by approximately 1 year of age. However, infection with the combination of RCAS-shNf1 and RCAS-shp53 led to the formation of gliomas in 100% of mice, with a median survival of 146 days for G/tv-a (n = 52) and 221 days for N/tv-a (n = 32) mice (Figures 5A and 5B; . These latencies are similar to those published for gliomas formed by germline models of combined Nf1 and p53 loss (Reilly et al., 2000; Zhu et al., 2005) . Histologic analysis of the G/tv-a and N/tv-a tumors showed stronger expression of the MES markers vimentin and CD44, and the MES master regulators pSTAT3 and C/EBPb in the G/tv-a tumors than in the N/ tv-a tumors ( Figure 5B and data not shown) (Carro et al., 2010) . Gene expression profiling of these tumors (G/tv-a, n = 7; N/tv-a, n = 11) demonstrated that they were more MES-like than those driven by PDGFA ( Figure 4F ) and that gliomas arising in G/tv-a mice had a more MES-like expression pattern than those arising in N/tv-a mice ( Figure 5C ). Collectively, these data suggest that it is possible to generate MES gliomas from normal cells in postnatal mice with a similar latency to that seen with germline strategies that delete both genes (Reilly et al., 2000; Zhu et al., 2005) . While Nf1 loss in N/tv-a;Cdkn2a À/À ;Pten fl/fl mice was considerably less efficient than loss of Tp53 for the formation of gliomas, as supported by the fact that NF1 loss is associated with TP53 mutations and, less commonly, CDKN2A loss (Figures S5A and  S5E; Table S7 ) (Verhaak et al., 2010) .
Additional Loss of NF1 Converts the PDGFA-Induced PN Phenotype to a MES Gene Expression Pattern
The tumor latency for PDGFA-induced gliomas versus those induced by Nf1 loss is striking. In the mouse model, the loss of both Nf1 and Tp53 occurs simultaneously, whereas in humans, there would be multiple separate mutational events in a normal cell that would lead to loss of function of both alleles of NF1 and mutation of TP53. Such an evolutionary pathway to MES GBMs formation, although possible, might be much slower than that for PN GBMs, which requires elevated expression from a single gene, such as PDGFA. Moreover, the importance of the chronological order of mutations in MES glioma formation is underscored by the fact that, in mice, loss of Nf1 is less efficient at enhancing gliomas than loss of Tp53 in the context of forced PDGFA expression ( Figure 4B ). Finally, global copy number and RESIC analysis predicts that MES GBMs initially arise from tumors with the same alterations as PN GBMs and that they lose NF1 later (Figure 2) . Therefore, we sought to determine whether NF1 loss in PN-GBM could induce a PN-to-MES GBM transition. We obtained two PN GBM cell lines that contain an amplification of PDGFRA, and, by expression profiling, fit the criteria for the PN subtype (Figures 6A and 6B ; Figures S6A and S6B) (Ozawa et al., 2010) . Expression profiling of the lines before and after NF1 knockdown showed that the original PN expression pattern was shifted toward a MES or CL pattern in both cases ( Figure 6B ; Figures  S6B and S6C) . Moreover, knockdown of Tp53 or Nf1 alone was sufficient to induce PN and MES gene enrichment in murine neurosphere culture, respectively ( Figure 6C ; Figure S6D ). These results suggest that NF1 function regulates transcriptional pathways necessary for mesenchymal conversion. To examine whether NF1 directly regulates the expression of mesenchymal transcriptional factors (TFs), we performed a TF enrichment analysis in murine neurosphere ( Figure S6E ), murine glioma (Figure S6F) , and TCGA ( Figure S6G ) data sets. We identified 14 TF gene sets (MSigDB 4.0) corresponding to 9 different TFs, that were significantly (FDR < 0.05) associated with NF1 loss in the three data sets ( Figure 6D; Figures S6E-S6G) . Some of these 14 TF gene sets associated with NF1 loss presented a high similarity to each other ( Figure 6D ) and displayed a significant overlap with recently reported mesenchymal TF target genes (Carro et al., 2010) (Figure 6E ). Notably, NF1 loss was associated significantly with two main mesenchymal TFs, C/EBPb and RUNX1 (Figure 6F) . By contrast, perturbations of STAT3 and C/EBPb expression did not affect NF1 expression in human GBM cells and mouse stem cells ( Figures S6H and S6I) , implying that these MES-associated TFs are downstream of NF1 loss. ShNf1-induced tumors showed a statistically significant association between loss of NF1 and gene expression changes related to the mammalian target of rapamycin (mTOR) pathway ( Figure S6J ). Furthermore, loss of NF1 did not appreciably elevate Erk or Akt phosphorylation (p) but did elevate pS6RP, suggesting that NF1 loss may affect mTOR activity in an Akt-independent manner ( Figure 6A ). Therefore, we treated the two NF1 knockdown cell lines with the mTOR inhibitor rapamycin ( Figure S6K ) and observed a marked but variable shift from MES/CL toward PN expression, suggesting that blockade of mTOR rescues the effect of NF1 loss in PN GBM lines ( Figure 6B ).
Finally, we determined whether NF1 loss could convert PN GBMs to MES GBMs in mice. To test sequential loss, we initially generated PDGFA/shp53 tumors by concurrent stereotactic injection of the two vectors and then secondary infection with the GFP-shNf1 vector into the tumors using the same stereotactic coordinates 2-4 weeks later. The RCAS-GFP-shNf1 virus was incorporated regionally in 15 of 20 mouse gliomas (Table S7) was associated preferably with GFP-positive regions (i.e., NF1 knockdown) and/or adjacent areas ( Figure 7A ). For simultaneous loss of NF1, we compared the GBMs generated by the double combination of RCAS-PDGFA and RCAS-shp53 (G/tv-a, n = 31; N/tv-a, n = 18; see above) to the triple combination of RCAS-PDGFA, RCAS-shp53, and RCAS-shNf1 (G/tv-a, n = 26,; N/tv-a, n = 18). The additional loss of Nf1 in the triply infected mice resulted in gliomas occurring significantly faster than the doubly infected mice, both from the G/tv-a ( Figure 7B , right panel) and the N/tv-a ( Figure 7B , left panel) cell of origin. The expression patterns for the two populations showed that the doubly infected mice generated gliomas with a PN gene expression pattern ( Figures 4F and 7C ), whereas the gliomas from the triply infected mice shifted toward MES ( Figure 7C ).
DISCUSSION
There has been much discussion about the implications of the molecular subgroups of GBM. The data presented here connect the GBM subtypes in an evolutionary framework where the primordial tumors are PN in character, with the other subgroups evolving from them. Amplification of PDGFRA occurs primarily in tumors that remain PN. Mathematical modeling suggests that chr7 gain and chr10 loss are very common early genetic events in all subtypes of non-GCIMP GBM. Further, we found that the selective advantage for additional copies of chr7 is primarily, but potentially not exclusively, driven by elevated expression of PDGFA and that a primary driver for loss of chr10 is reduced expression of PTEN. These predictions were supported by mouse modeling data indicating that overexpression of PDGFA was sufficient to induce gliomas that were enhanced by PTEN loss to give rise to GBM with a PN character. Note that chr7 encodes many other genes with elevated copy number by the gain of chr7, which may contribute to oncogenesis and therapeutic resistance. Similarly, there could be genes on chr10 additional to PTEN whose loss enhances oncogenesis or alters the therapeutic response early in GBM evolution. Loss of chr10, which occurs in nearly all non-GCIMP GBMs, is represented by one copy loss. Therefore, it is intriguing to know whether loss of function of the remaining allele is essential in non-GCIMP GBM formation. A nonsilent somatic point mutation in the remaining PTEN allele is found in 37.9% of all cases with a single copy of chr10, and homozygous deletion was identified in 10% of non-GCIMP GBMs. Given that PTEN expression is also regulated by promoter methylation and microRNA, the remaining PTEN allele might be also inactivated by alternative mechanisms in non-GCIMP GBMs ( expression decreased from diploid to hemi-and homozygous loss in non-GCIMP GBMs. In mice, heterozygous loss of Pten was sufficient to induce gliomas in combination with Tp53 loss, with or without Nf1 loss, and the homozygous loss increased the aggressiveness of tumors (Kwon et al., 2008; Zheng et al., 2008) . Therefore, heterozygous loss of PTEN appears to be enough for initiating an abrogation of gene function in GBM patients.
Mouse models can demonstrate that specific cell types, gene combinations, and sequences of events are sufficient to form tumors, but they alone do not prove that human tumors form that way. The mathematical analysis of human GBM data presented here indicates that a specific set and order of gene abnormalities represent the major evolutionary pathway toward non-GCIMP GBM. The mouse modeling shows that this specific predicted series of events is sufficient to form PN-like GBM in mice and that this character can be shifted to a MES one with subsequent loss of Nf1, predicted to be a late event in the evolution of MES GBM in humans. Further, given the highly similar copy number patterns for most non-GCIMP GBM subtypes, it is likely that most non-GCIMP GBM subtypes arise similarly.
Our studies suggest that cells harboring both chr7 gain and chr10 loss are the most likely cells of origin for gliomas. However, given the existence of a few cases of GBM in the TCGA data set without copy number alterations of both chromosomes, there clearly are exceptions. Indeed, as shown by our Nf1/Tp53 loss model, it is possible that MES GBMs could arise de novo via a different cell of origin and evolutionary pathway. Furthermore, the relatively rare patients without chr10 loss have significantly more whole chromosome 12 gains (FDR < 0.01), and patients without chr7 gain have significantly higher odds of a PDGFRA somatic mutation (p = 0.05, Fisher's exact test). This might also indicate that pathways affected by chr7 gain and chr10 loss can be interrupted with similar consequences by alterations on other chromosomes. Nonetheless, the majority of non-GCIMP GBMs are abnormal for chr7 and chr10 and most likely arise from a PN-like precursor lesion.
This series of molecular events early in the development of GBM is different from that seen in other cancer types induced by point mutations or translocations with the generation of a single oncogene in an otherwise normal background, such as chronic myeloid leukemia (Hehlmann et al., 2007) . The acquisition of multiple pro-oncogenic alterations by copy number gain and loss at the outset of tumor formation would reduce the likelihood of success for targeted therapy against any specific signaling targets, especially those acquired late in the tumor's evolution. The data argue that PDGFA is the gene on chr7 that most likely provides the strongest selection for initial gain of chr7 at the beginning of non-GCIMP GBM formation. However, other genes on chr7, such as CUL1, CBLL1, ASNS, ARPC1A, and GLI3, might have similar but less robust effects and could collectively trump PDGFA expression later in GBM evolution. It remains to be elucidated how our findings relate to other tumor types that also show gains of large portions of chr7 and loss of chr10.
The chromosomal abnormalities early during GBM evolution are interesting in light of the observation that aneuploidy for at least one chromosome occurs in as many as 10% of all cells in the normal adult brain (Iourov et al., 2006; Iourov et al., 2009) and is even higher during development, reaching 30%-35% (Bushman and Chun, 2013; Yurov et al., 2007) . This higher prevalence in the brain compared with other organs has been suggested to contribute to neuronal diversity (Bushman and Chun, 2013) . However, from this diverse set of errors in chromosomal number throughout the normal brain, only cells with loss of one copy of chr10 and gain of variable numbers of chr7 give rise to non-GCIMP GBMs. Given the prevalence of aneuploid cells in the normal brain, it is likely that many cells with both gain of chr7 and loss of chr10 exist in each individual. Therefore, other mechanisms may contribute to the fact that GBMs are not more prevalent. If aneuploidy in the CNS functions to generate neuronal diversity, we might speculate that the risk of developing GBM may be the price paid for complex CNS function.
EXPERIMENTAL PROCEDURES Data Sets of Human GBM Samples
We obtained segmented copy number data, raw and normalized mRNA expression data, methylation data, and somatic mutation data from the TCGA (The Cancer Genome Atlas Research Network, 2008). All analyses were done in R/Bioconductor (Gentleman et al., 2004) . The details of all bioinformatic analyses are described in the Supplemental Experimental Procedures.
Phylogenetic Analysis
To examine the relationship between GBM subgroups, we applied the Neighbor-Joining algorithm (Saitou and Nei, 1987) independently to the TCGA GBM Agilent expression, SNP copy number, promoter methylation, and somatic mutation data, as described previously (Riester et al., 2010) .
RESIC Analysis
To determine the temporal sequence of genetic alterations, two whole chromosome events, chr7 non-disjunction and chr10 loss, as well as subtype-defining events (focal EGFR gain and amplification, PDGFRA gain and amplification, and NF1 loss), we applied the RESIC algorithm to the GBM data set, as described previously Cheng et al., 2012) .
Pathway Analysis
To prioritize genes in large copy number alterations, we developed a computational method. The algorithm identifies genes from disease-related pathways for which copy number gain has a profound impact on mRNA levels.
Transcription Factor Analysis
To examine whether NF1 loss had an impact on expression of certain TFs, a gene set enrichment analysis (GSEA) was performed with MSigDB 4.0, which provides 615 putative TF/target gene sets (c3 category) (Subramanian et al., 2005) .
Gene Expression Analysis for Murine Brain Tumors and
Neurosphere and Human GBM Cell Lines Total RNAs were labeled by the Illumina protocol, followed by hybridization to the BeadChip (Illumina). Raw data were processed at the Genomics Core Laboratory of Memorial Sloan-Kettering Cancer Center (MSKCC) and then normalized with the lumi R package (Du et al., 2008) . For the GSEA, the Verhaak et al. subtype signatures were used (Verhaak et al., 2010) .
Vector Constructs
The human PDGFA cDNA was purchased from OriGene Technologies and was subcloned into the RCAS-Y vector (Dunn et al., 2000) . For the generation of the RCAS-shRNA vector, shRNAs were initially assembled in the pSUPER.retro.puro vector (OligoEngine) or the pENTR-mRFP-H1 vector. The shRNAs containing the H1 promoter were PCR-amplified and then inserted into the RCAS-Y vector. For the pENTR-mRFP-H1 vector, LR recombination was used to transfer the shRNA containing H1 and mRFP into the RCAS-Destination vector (Loftus et al., 2001 ) (see also Supplemental Experimental Procedures).
Generation of Murine Brain Tumors
All animal experiments were done in accordance with protocols approved by the Institutional Animal Care and Use Committees of MSKCC and Fred Hutchinson Cancer Research Center and followed NIH guidelines for animal welfare. The RCAS/tv-a system used in this work has been described previously (Holland et al., , 2000 Hu et al., 2005; Uhrbom et al., 2004) ;Pten fl/fl mice were used for the RCASmediated gliomagenesis in this study. After injection of the relevant RCAS virus, mice were observed until they developed brain tumor-related symptoms unless there was a particular note (see also Supplemental Experimental Procedures).
Hematoxylin and Eosin Staining and Immunohistochemistry
Mouse brains were prepared for paraffin and sectioning and stained with hematoxylin and eosin as described previously Holland et al., 2000) . Briefly, immunohistochemical staining was performed with an automated staining processor (Hambardzumyan et al., 2008) . The antibodies used in this study are described in the Supplemental Experimental Procedures. The histological diagnosis and tumor grade was established based on the World Health Organization (WHO) criteria (Huse et al., 2009; Louis et al., 2007) .
Western Blot Analysis
Cells were cultured, lysed with NF1 lysis buffer (Yunoue et al., 2003) , and processed for Western blotting by standard methods. The antibodies used in this study are described in the Supplemental Experimental Procedures.
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